Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...

The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that ...

The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...

Oil prices fell on Friday on signs demand in China, the world's biggest crude importer, continues to underperform amid its ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

Premier alleges the Health Resources and Services Administration lacks authority to enforce a policy restricting how 340B ...

The Medical University of South Carolina has been awarded $1.75 million from the Health Resources and Services Administration ...

Johnson & Johnson’s rebate model aims to address misuse of 340B Program. HRSA’s threats of penalties led J&J to halt the plan ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...